Gene therapy shot aims to cut eye injections for diabetic vision loss

NCT ID NCT05930561

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial tests a gene therapy called 4D-150 for diabetic macular edema, a condition that causes vision loss in people with diabetes. The study involves 72 adults who will receive either the gene therapy or standard aflibercept injections. The goal is to see if a single dose of gene therapy can reduce the need for frequent eye injections over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
4D-150 gene therapy
What this could lead to
If successful, this gene therapy could reduce the number of eye injections needed to control diabetic macular edema, potentially improving quality of life.
What could go wrong
This is an early phase 2 trial with only 72 participants. The therapy may not work as hoped, and there are risks from the injection and gene therapy itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Austin Clinical Research

    Austin, Texas, 78750, United States

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland, 21740, United States

  • Emanuelli Research and Development Center

    Arecibo, X00612, Puerto Rico

  • Erie Retina Research

    Erie, Pennsylvania, 16507, United States

  • Piedmont Eye Center

    Lynchburg, Virginia, 24502, United States

  • Verum Research, LLC

    Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.